| |
| |
|
| Insider
Information: |
Leung Sandra |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
348,885 |
|
|
Indirect Shares
|
100,721 |
|
|
| Direct
Value |
$15,580,217 |
|
|
|
Indirect Value
|
$4,517,337 |
|
|
| Total
Shares |
449,606 |
|
|
| Total
Value |
$20,097,554 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 7.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Bristol-Myers Squibb Co |
BMY |
EVP, General Counsel |
2024-03-10 |
347,385 |
2024-03-10 |
100,721 |
Premium* |
|
|
Mead Johnson Nutrition Co |
MJN |
Director |
2009-02-17 |
1,500 |
2009-02-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2024-03-10 |
4 |
D |
$53.79 |
$896,141 |
D/D |
(16,660) |
347,385 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,153) |
359,080 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,784 |
371,312 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2023-11-21 |
4 |
A |
$48.75 |
$479,163 |
I/I |
9,830 |
93,436 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2023-11-21 |
4 |
D |
$48.75 |
$479,163 |
D/D |
(9,830) |
331,414 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2023-03-10 |
4 |
D |
$65.71 |
$2,240,974 |
D/D |
(34,104) |
341,244 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,731 |
361,160 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
57,990 |
356,920 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2022-06-06 |
4 |
S |
$74.89 |
$4,867,850 |
D/D |
(65,000) |
308,627 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2022-03-10 |
4 |
D |
$68.42 |
$3,072,126 |
D/D |
(44,901) |
373,627 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
18,288 |
403,642 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
60,273 |
388,747 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2021-07-30 |
4 |
S |
$68.04 |
$1,999,696 |
D/D |
(29,390) |
339,967 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2021-03-10 |
4 |
D |
$60.93 |
$1,901,016 |
D/D |
(31,200) |
369,357 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,554 |
387,579 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,373 |
383,564 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2021-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(413) |
351,776 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2020-08-13 |
4 |
S |
$63.24 |
$8,943,401 |
D/D |
(141,420) |
432,744 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2020-03-10 |
4 |
D |
$57.93 |
$1,640,114 |
D/D |
(28,312) |
574,164 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,096 |
591,284 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,598 |
588,175 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(298) |
555,623 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$1,038,335 |
D/D |
(20,205) |
546,080 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,170 |
558,854 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,509) |
534,266 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
